CD161 + CD127 + CD8 + T cell subsets can predict the efficacy of anti-PD-1 immunotherapy in non-small cell lung cancer with diabetes mellitus-Reference-Cited by-同舟云学术

CD161 ⁺ CD127 ⁺ CD8 ⁺ T cell subsets can predict the efficacy of anti-PD-1 immunotherapy in non-small cell lung cancer with diabetes mellitus

Published:2024-06-27 Issue:1 Volume:13 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Qu Jingjing¹²^ORCID,Li Yuekang¹²,Wu Binggen¹²,Shen Qian¹²,Chen Lijun³,Sun Wenjia¹²,Wang Bo⁴,Ying Lixiong⁴,Wu Li⁵,Zhou Hong¹,Zhou Jianya¹²,Zhou Jianying¹²

Affiliation:

1. Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China

2. The Clinical Research Center for Respiratory Diseases of Zhejiang Province, Hangzhou, Zhejiang, P. R. China

3. State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P.R. China

4. Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China

5. Department of Endocrinology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China

Funder

Natural Science Foundation of Zhejiang Province

National Natural Science Foundation of China

Medicine Health Technology Plan of Zhejiang Province, China

General Project of Education Department of Zhejiang Province

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2024.2371575

Reference66 articles.

1. Cancer incidence, mortality, and burden in China: a time‐trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020

2. Toward personalized treatment approaches for non-small-cell lung cancer

3. Emerging evidence and treatment paradigm of non-small cell lung cancer

4. At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC

5. Combination strategies to maximize the benefits of cancer immunotherapy